Question 1

Which medications contribute the highest anticholinergic burden?

Accepted Answer

Tricyclic antidepressants (especially amitriptyline, nortriptyline, doxepin), first-generation antihistamines (diphenhydramine, hydroxyzine), antimuscarinics for overactive bladder (oxybutynin, tolterodine), and antipsychotics (especially clozapine, olanzapine) are among the most potent contributors. These are usually scored at level 2 or 3.

Question 2

Can anticholinergic burden be reduced without compromising symptom control?

Accepted Answer

Often yes — alternatives with lower or no anticholinergic activity are available for most indications. For example, SSRIs (citalopram, sertraline) can replace tricyclic antidepressants; second-generation antihistamines (loratadine, cetirizine) replace first-generation; mirabegron replaces oxybutynin. Deprescribing should be done gradually and with monitoring.

Question 3

Is there a link between anticholinergic burden and dementia?

Accepted Answer

Yes — prospective cohort studies have found an association between high anticholinergic burden (particularly cumulative exposure) and increased risk of incident dementia. The risk appears to be dose- and duration-dependent. Reducing unnecessary anticholinergic exposure in middle-aged and older adults is a recommended dementia prevention strategy.

Question 4

Does topical or ocular anticholinergic medication contribute to the burden?

Accepted Answer

Topical routes (eye drops, inhalers, topical creams) can contribute to systemic anticholinergic burden, though usually to a lesser degree than oral medications. Atropine eye drops, ipratropium inhalers, and topical anticholinergics should be included in the assessment, especially when used chronically.